Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting
May 09, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., May 09, 2022 ...
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress
April 25, 2022 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the...
U.S eClinical Solutions Market Research 2022 Report: Examines the $1.3+ Million Industry
April 12, 2022 06:08 ET
|
Research and Markets
Dublin, April 12, 2022 (GLOBE NEWSWIRE) -- The "eClinical Solutions Market Research Report by Product, by Delivery Mode, by Development Phase, by End-user, by State - United States Forecast to 2027...
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
April 07, 2022 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create...
Triphase Accelerator Announces Positive Updated Phase 1 Data with TRPH-222 in Non-Hodgkin’s Lymphoma
February 22, 2022 08:00 ET
|
Triphase Accelerator
High response rates: ORR of 54% and a CR rate of 38%Durable responses: ~25 months median duration of response Favourable safety profile: AEs predominantly low grade, tolerable, easily managed, and...
Sema4 to Participate at Two Upcoming Investor Conferences in February
February 03, 2022 16:05 ET
|
Sema4
STAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will...
Q-Centrix and Datavant Partner to Expand Enterprise Clinical Data Management and Securely Connect Clinical Data
February 01, 2022 09:00 ET
|
Q-Centrix
CHICAGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Q-Centrix, the largest exclusive provider of clinical data management solutions to health systems, today announced a partnership with Datavant, the leader...
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
January 18, 2022 07:00 ET
|
Sema4
Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify...
Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021
January 10, 2022 07:15 ET
|
Sema4
STAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced preliminary revenue (unaudited) for the...
Insights on the eClinical Solutions Global Market to 2026 - Featuring Acceliant, Bioclinica and Medrio Among Others
January 07, 2022 05:03 ET
|
Research and Markets
Dublin, Jan. 07, 2022 (GLOBE NEWSWIRE) -- The "eClinical Solutions Market Research Report by Product, Delivery Mode, Development Phase, End-user, and Region - Global Forecast to 2026 - Cumulative...